|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
The pharmaceutical industry has been moving away from the traditional research-driven business model to one that is motivated by the marketing of major branded products. Compelled by the need to create bestseller products and then defend their sales post-patent expiry, pharmaceutical companies are increasingly using the power of branding to capture the hearts and minds of the public.
Colours are often the central element of a product's branding, and reputation can be built on colour alone. By way of example, AstraZeneca's Losec was promoted as the 'purple pill' in advertisements, and the replacement for Losec - Nexium - is the same colour and is referred to as 'the new purple pill'. Also, in advertisements for Pfizer's Viagra, Bob Dole refers to the pill as his 'little blue friend'. So to what extent can companies protect the colours of their products and packaging as national trademarks in the UK, or alternatively as community trademarks (CTMs)?
This article will briefly discuss the advantages of registered Trademarks and the approach taken by the UK Trade Marks Registry and the Office of Harmonisation for the Internal Market (OHIM) (which grants CTMs) towards the registration of colours as trademarks. It will then discuss the recent European Court of Justice (ECJ) decision in Libertel Groep BV v Benelux-Merkenbureau (1), which will have an important impact on the way in which EU trademark offices will approach applications to register colour marks in the future and consequently on the way colours will be used in the pharmaceutical industry as source identifiers.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Aptar Pharma Launches First Metal-Free Nasal Spray Pump, Meeting Growing Need for Highly Recyclable Packaging
Crystal Lake, Illinois, January 30, 2023 - Aptar Pharma, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery systems, services and active material science solutions, today announces the launch of APF Futurity, its first metal-free, multidose nasal spray pump developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial-Specific Travel Programs as a Patient Retention Tool
For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >> |
|
|
